Type 1 Diabetes Trial, Recruiting NCT06283797 Sponsor: University Hospital, Montpellier Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Type 1 Diabetes Trial, Recruiting

NCT06283797
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children and teenagers aged between 2 and 17 years and 11 months old
  • People who have been diagnosed with type 1 diabetes for at least 3 months but no more than 6 months, based on World Health Organization standards
  • People who have tested positive for at least one of the following diabetes-related markers in their blood: anti-GAD, anti-IA2, anti-ZnT8, or anti-insulin antibodies
  • People who are currently managing their diabetes using multiple daily insulin injections or an insulin pump (including pumps that can pause automatically if low blood sugar is predicted)
  • The patient and/or their parents or guardians must have been trained in counting carbohydrates in food
  • The patient and/or their parents or guardians must own a smartphone that supports the Dexcom G6 app, and those involved must be willing to use the Dexcom G6 sensor and app for the entire duration of the study

Who may not be able to join:

  • Cases where a parent or legal guardian is unwilling to be involved in the child's insulin treatment
  • People who have another ongoing long-term condition or are taking medications (other than insulin or a stable dose of L-thyroxine) that affect blood sugar levels
  • People who are already using a fully automated insulin delivery system that connects an insulin pump to a continuous glucose monitor with a control algorithm (also called a hybrid closed-loop system)
  • People who have a skin allergy or skin reaction to the adhesives used in glucose monitors or insulin pods
  • People who have vision or hearing difficulties that would prevent them from using all the features of the Omnipod 5 system, including its alerts and alarms
  • Cases where the patient and/or their parents or legal guardian have cognitive or psychological difficulties that may make it hard to follow the study procedures reliably
  • People who are currently enrolled in another clinical trial or who have received an unapproved medication within the 4 weeks before the screening date
  • People who have an employment or dependent relationship with the organisation running or sponsoring the trial
  • Cases where the patient and their parents or legal guardian have not signed the required consent form
  • People who would be unable to attend all required appointments or follow all trial procedures
  • People who are under legal protection or who have had their liberty restricted by law
  • People who are pregnant or breastfeeding
  • People who are not covered by public health insurance

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Eric RENARD, MD, University Hospital, Montpellier

Phone: 04 67 33 83 82

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
29 May 2024
Est. completion
29 June 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Glycated hemoglobin (HbA1c) level

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov